Post Wed Nov 23, 2022 6:13 pm

2022-Tan et al-Nat Commun

"A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma"
Tira J Tan, W X Gladys Ang, Who-Whong Wang, Hui-Shan Chong, Sze Huey Tan, Rachael Cheong, John Whay-Kuang Chia, Nicholas L Syn, Wai Ho Shuen, Rebecca Ba, Nivashini Kaliaperumal, Bijin Au, Richard Hopkins, Xinhua Li, Aaron C Tan, Amanda O L Seet, John E Connolly, Thaschawee Arkachaisri, Valerie Chew, Ahmad Bin Mohamed Lajam, Dianyan Guo, Marvin Z W Chew, Martin Wasser, Pavanish Kumar, Salvatore Albani, Han Chong Toh
Nat Commun. 2022, 13, 6453

- "Data availability

Data availability is subject to local rules and regulations. Subjects did not provide consent for their data to be made publicly available. However, every reasonable effort will be made to promptly satisfy scientifically valid requests. Requests for data should be made to the corresponding authors together with a detailed study plan and a commitment not to use the data and its derivatives for commercial purposes. The proposal will require approval by the SingHealth Centralised Institutional Review Board, National Cancer Centre Singapore (NCCS), Singapore Clinical Research Institute (SCRI), and the Principal Investigators of the study. Requesting researchers will be required to sign a data access agreement with the relevant parties. Upon signing, a mini dataset of de-identified raw data relevant to the results shown in the manuscript will be uploaded to a password protected account. Patient-related data were generated as part of a clinical trial and are subject to patient confidentiality. Access to de-identified clinical data, raw ELIspot and ELISA assay data can be made available for a period of 2 years."